Diaceutics PLC
LSE:DXRX

Watchlist Manager
Diaceutics PLC Logo
Diaceutics PLC
LSE:DXRX
Watchlist
Price: 116 GBX
Market Cap: 97.9m GBX
Have any thoughts about
Diaceutics PLC?
Write Note

Diaceutics PLC
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Diaceutics PLC
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Diaceutics PLC
LSE:DXRX
Current Portion of Long-Term Debt
ÂŁ146k
CAGR 3-Years
N/A
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Current Portion of Long-Term Debt
ÂŁ4.3m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Current Portion of Long-Term Debt
ÂŁ129k
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Current Portion of Long-Term Debt
ÂŁ1.6m
CAGR 3-Years
-7%
CAGR 5-Years
170%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Current Portion of Long-Term Debt
ÂŁ253k
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Current Portion of Long-Term Debt
ÂŁ1.4m
CAGR 3-Years
-12%
CAGR 5-Years
48%
CAGR 10-Years
24%
No Stocks Found

Diaceutics PLC
Glance View

Market Cap
98.3m GBX
Industry
Life Sciences Tools & Services

Diaceutics Plc engages in the provision of data, data analytics and implementation services. The company is headquartered in Belfast, Northern Ireland. The company went IPO on 2019-03-21. The principal activity of the Company is data analytics and implementation services. The firm is engaged in research and development activities in drug development science, testing data and software platform development. The firm's implementation services include test standardization, test quality assessment, laboratory tech support and others. The firm has established a range of products and outsourced advisory services, which help its pharma clients to optimize and deliver their marketing and implementation strategies for companion diagnostics. The firm provides the pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network. DXRX is the diagnostic commercialization platform for precision medicine, integrating multiple pipelines of diagnostic testing data from a global network of laboratories.

DXRX Intrinsic Value
155.87 GBX
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Diaceutics PLC's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
146k GBP

Based on the financial report for Dec 31, 2023, Diaceutics PLC's Current Portion of Long-Term Debt amounts to 146k GBP.

What is Diaceutics PLC's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
-21%

Over the last year, the Current Portion of Long-Term Debt growth was 18%.

Back to Top